PubRank

Cynthia M Westerhout

Author PubWeight™ 42.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation 2008 2.19
2 Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003 1.90
3 Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004 1.82
4 Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail 2008 1.68
5 Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 2011 1.58
6 Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. Eur Heart J 2012 1.53
7 Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ 2012 1.45
8 Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. Am Heart J 2010 1.43
9 Acute heart failure: perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail 2012 1.42
10 Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010 1.36
11 Effects of socioeconomic status on mortality after acute myocardial infarction. Am J Med 2007 1.24
12 Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. Arch Intern Med 2003 1.19
13 ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation 2011 1.13
14 Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 2009 0.94
15 Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. CMAJ 2007 0.93
16 High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. Am Heart J 2011 0.90
17 Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2009 0.90
18 Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med 2007 0.89
19 Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 2006 0.88
20 Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health 2005 0.87
21 Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 2010 0.87
22 Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. Eur Heart J 2006 0.86
23 Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010 0.86
24 Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. JACC Cardiovasc Interv 2010 0.86
25 Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. Am Heart J 2007 0.85
26 Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event. Am Heart J 2008 0.84
27 Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur Heart J 2008 0.83
28 The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients? Am Heart J 2013 0.81
29 Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. JACC Cardiovasc Interv 2010 0.81
30 Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2012 0.78
31 Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J 2013 0.78
32 Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. J Electrocardiol 2010 0.77
33 Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. Eur Heart J 2009 0.77
34 Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2010 0.77
35 The relationship between meteorological conditions and index acute coronary events in a global clinical trial. Int J Cardiol 2013 0.76
36 Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials. Curr Opin Investig Drugs 2004 0.76
37 Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. J Thromb Thrombolysis 2012 0.76
38 Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. Am Heart J 2013 0.76
39 Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. Int J Biometeorol 2012 0.75
40 Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. Can J Cardiol 2009 0.75
41 ST-segment resolution and outcome in myocardial infarction. J Am Coll Cardiol 2010 0.75
42 The power of more than one. Circulation 2013 0.75
43 A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 2007 0.75
44 Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2012 0.75
45 Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Am Heart J 2009 0.75
46 Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. Am J Med 2013 0.75
47 Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. Contemp Clin Trials 2008 0.75
48 Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheter Cardiovasc Interv 2014 0.75
49 Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: implications for strategic management. Am Heart J 2011 0.75